Biophan Technologies CEO to Present Today at Nanotechnology Conference at Rensselaer Polytechnic Institute.

ROCHESTER, N.Y. -- Biophan Head to Discuss the Latest Advances in Nanomedicine at Gathering of Scientists and Members of the Industry and Investment Communities

Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has announced that Company CEO Michael Weiner will present today at the "Nanotechnology: Innovation, Opportunity, and Commercialization" conference at Rensselaer Polytechnic Institute in Troy, N.Y.

In a presentation entitled, "Solutions for making Biomedical Devices Safe and Image Compatible with MRI," Mr. Weiner will provide commentary regarding the Company's latest innovations in nanotechnology for a range of biomedical solutions, including MRI-guided surgery, drug-elution, and other initiatives.

Mr. Weiner's presentation can be viewed online at http://www.biophan.com/presentations/RPI.html or http://www.biophan.com/presentations/RPI.ppt.

Further information about Biophan innovations in MRI-guided surgery can be viewed at http://www.biophan.com/pr/080904NanosetWebsite_and_print.html

"As nanotechnology increasingly intersects with medicine, biotechnology, and engineering, it is critical that the industry leaders stay in close communication with researchers in academia and government," Mr. Weiner explained. "This is a rapidly evolving and highly promising field, and because of its focus on nano-enabled biomedical technologies, Biophan is excited to be a part of this important gathering at RPI."

"Enabling biomedical devices to be safe and image-compatible under MRI conditions has been a core mission at Biophan," Mr. Weiner said. "We are using nanotechnologies to advance the capabilities of physicians to use MRI with a much wider range of patients, enabling those with a variety of medical devices to reap the benefits of MRI previously unavailable to them."

The two-day conference is sponsored by RPI in concert with a consortium of leading players in nanobiotechnology science, researchers from government and academia, business and economic development professionals, policy makers, and intellectual property practitioners.

About Rensselaer Nanotechnology Center

The Rensselaer Nanotechnology Center, based at Rensselaer Polytechnic Institute in Troy, N.Y., provides a major resource to advance the scientific promise represented by nanotechnology, as well as providing interdisciplinary programs to educate new generations of students. Industry support of the Rensselaer Nanotechnology Center has been established through the RPI-Industry Partnership in Nanotechnology, which supports Rensselaer's research and educational efforts in nanotechnology. For more information about the conference, visit http://www.alumni.rpi.edu/nanotech.html.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending or allowed.

This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.